| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLAU |
| Uniprot No | P00749 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-431aa |
| 氨基酸序列 | SNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTC YEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHN YCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQ KTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVI SATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTL AHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGK ENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTD SCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIR SHTKEENGLAL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与PLAU(uPA)重组蛋白相关的文献摘要信息：
1. **文献名称**：*"Functional characterization of recombinant human urokinase-type plasminogen activator produced in Escherichia coli"*
**作者**：Appella E. et al.
**摘要**：研究报道了在大肠杆菌中表达重组人uPA的方法，通过体外复性获得具有酶活性的蛋白，并验证其纤溶功能及与受体的结合能力。
2. **文献名称**：*"Structural basis of plasminogen activation by urokinase: Potential drug target for thrombosis"*
**作者**：Smith R.A. et al.
**摘要**：解析了重组uPA的晶体结构，阐明其激活纤溶酶原的分子机制，提出通过抑制uPA活性开发抗血栓药物的策略。
3. **文献名称**：*"Recombinant urokinase-derived peptides suppress tumor cell invasion by blocking uPAR/PLAU interaction"*
**作者**：Li S. et al.
**摘要**：利用重组uPA片段设计多肽抑制剂，成功阻断uPA与其受体uPAR的结合，抑制肿瘤细胞体外侵袭和转移。
(注：以上为模拟文献摘要，实际文献需通过数据库检索获取。)
**Background of PLAU Recombinant Protein**
The plasminogen activator, urokinase (PLAU), also known as urokinase-type plasminogen activator (uPA), is a serine protease encoded by the *PLAU* gene. It plays a critical role in extracellular matrix (ECM) degradation by converting plasminogen into plasmin, a broad-spectrum protease involved in fibrinolysis, tissue remodeling, and cell migration. Structurally, PLAU consists of an N-terminal growth factor-like domain, a kringle domain, and a catalytic serine protease domain. Its activity is tightly regulated by interactions with its receptor (uPAR) and inhibitors like PAI-1.
Recombinant PLAU protein is engineered using biotechnological platforms, such as mammalian or bacterial expression systems, to produce functional uPA for research and therapeutic applications. It is typically generated by cloning the *PLAU* gene into expression vectors, followed by purification via affinity chromatography. Recombinant PLAU retains enzymatic activity and is utilized to study cancer metastasis, wound healing, and inflammatory diseases, where ECM remodeling and cell invasion are pivotal.
Clinically, recombinant PLAU has been explored for thrombolytic therapy to dissolve blood clots, though its systemic use is limited due to bleeding risks. Recent advances focus on engineering PLAU variants with improved specificity or reduced side effects. Additionally, PLAU's role in tumor progression has made it a target for anticancer therapies, with inhibitors and antibody-based strategies under investigation. Overall, recombinant PLAU serves as a vital tool for understanding proteolytic cascades and developing interventions for fibrosis, thrombosis, and metastatic diseases.
×
